key: cord-1005307-uqvmsi3s
authors: Romagnoli, Renato; Gruttadauria, Salvatore; Tisone, Giuseppe; Maria Ettorre, Giuseppe; De Carlis, Luciano; Martini, Silvia; Tandoi, Francesco; Trapani, Silvia; Saracco, Margherita; Luca, Angelo; Manzia, Tommaso Maria; Visco Comandini, Ubaldo; De Carlis, Riccardo; Ghisetti, Valeria; Cavallo, Rossana; Cardillo, Massimo; Grossi, Paolo Antonio
title: Liver transplantation from active COVID‐19 donors: A lifesaving opportunity worth grasping?
date: 2021-09-13
journal: Am J Transplant
DOI: 10.1111/ajt.16823
sha: cc0cf60329ed4f92ea5acbf4bcd246ce56d805a2
doc_id: 1005307
cord_uid: uqvmsi3s

COVID‐19 pandemic dramatically impacted transplantation landscape. Scientific societies recommend against the use of donors with active SARS‐CoV‐2 infection. Italian Transplant Authority recommended to test recipients/donors for SARS‐CoV‐2‐RNA immediately before liver transplant (LT) and, starting from November 2020, grafts from deceased donors with active SARS‐CoV‐2 infection were allowed to be considered for urgent‐need transplant candidates with active/resolved COVID‐19. We present the results of the first 10 LTs with active COVID‐19 donors within an Italian multicenter series. Only two recipients had a positive molecular test at LT and one of them remained positive up to 21 days post‐LT. None of the other eight recipients was found to be SARS‐CoV‐2 positive during follow‐up. IgG against SARS‐CoV‐2 at LT were positive in 80% (8/10) of recipients, and 71% (5/7) showed neutralizing antibodies, expression of protective immunity related to recent COVID‐19. In addition, testing for SARS‐CoV‐2 RNA on donors’ liver biopsy at transplantation was negative in 100% (9/9), suggesting a very low risk of transmission with LT. Immunosuppression regimen remained unchanged, according to standard protocol. Despite the small number of cases, these data suggest that transplanting livers from donors with active COVID‐19 in informed candidates with SARS‐CoV‐2 immunity, might contribute to safely increase the donor pool. [Image: see text]

The coronavirus disease 2019 (COVID-19) pandemic dramatically impacted the landscape of organ donation and transplantation in Europe and United States. 1, 2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes for cellular entry the angiotensin converting enzyme 2 which is mostly expressed in lungs, explaining why the respiratory system involvement predominates. 3 Nevertheless, organ dysfunction beyond the lungs has been described as well, in particular liver injury was seen in 14%-53% of patients due to infection of liver cells, druginduced or within a systemic inflammatory syndrome. 4 European and American scientific societies recommend against the use of organs from donors with active SARS-CoV-2 infection and recommend donor SARS-CoV-2 screening to prevent inadvertent positive organ transplant. 5, 6 On the other hand, the Organ Procurement and Transplantation Network Ad Hoc Disease Transmission Advisory Commitee reviewed published literature until April 2021 and suggested that the decision to recover organs from donors with active COVID-19 should evaluate the recipient's risk mortality and the risk of transmission to surgical teams. 7 The pro-con debate is going on, waiting for real-life data. 8, 9 The current recommendations are based on the assumptions that (1) SARS-CoV-2 could be transmitted to the recipient through organ transplantation, (2) it could result in severe manifestations in immunosuppressed patients, (3) there are only limited targeted treatment options, and (4) longterm allograft outcomes related to the use of such organs are largely unknown. So far, 11 SARS-CoV-2 infected donors (active COVID-19), diagnosed after donation, without transmission to 18 different recipients have been published (one living liver donor, one platelet transfusion, two allogenic hematopoieticstem cell transplantations, and 13 kidneys and one liver from deceased donors). 7, [10] [11] [12] [13] [14] Unfortunately, three cases of proven SARS-CoV-2 transmission from lung donor to recipient (despite negative donor upper respiratory tract testing) have been reported. 7,14,15 However, donor-derived infection with viruses that infect the respiratory tract has been already described in the past and almost exclusively detected in lung recipients. 16 These risks must be balanced against the lifesaving benefit of organ transplantation to patients who might otherwise have limited opportunities for transplant, due to disease acuity, limited matches related to blood type or sensitization, and may not survive to receive another organ from a non-infected donor. Furthermore, wait-listed patients are at risk for COVID-19 due to multiple comorbid conditions and frequent healthcare contacts.

Italy has been the first European country to face the severe COVID-19 pandemic since February 2020 and our National

Healthcare System is enduring a tremendous pressure. In order not to compound the outbreak lethality with risking the lives of patients who need a lifesaving liver transplant (LT), all transplant Centers remained open, although a reduction in the activity was noted due to donor shortage. 17 Italian Transplant Authority (Centro Nazionale Trapianti, CNT) recommended to test all recipients and donors for SARS-CoV-2 RNA immediately before LT and, to expand the donor pool, starting from November 2020 grafts from deceased donors with active SARS-CoV-2 infection were allowed to be considered for urgent-need transplant candidates, who were known to be SARS-CoV-2 positive or with past COVID-19, and were able to sign an informed consent.

As scanty data exist regarding the safety of transplanting organs recovered from donors with active COVID-19, we present here the results of the first 10 consecutive LT cases with such donors within an Italian multicenter (five centers involved) national series.

We enrolled patients from November 20, 2020, to February 8, 2021.

Follow-up was closed on July 18, 2021.

The Organ Procurement and Transplantation Network Ad Hoc Disease Transmission Advisory Committee 7 defined active COVID-19 an immunocompetent donor with a history of confirmed COVID-19, less than 21 days from the date of disease onset and SARS-CoV-2 detected in a respiratory sample or an asymptomatic donor with detection of SARS-CoV-2 in a respiratory sample without a reliable remained unchanged, according to standard protocol. Despite the small number of cases, these data suggest that transplanting livers from donors with active COVID-19 in informed candidates with SARS-CoV-2 immunity, might contribute to safely increase the donor pool.

cirrhosis, clinical research/practice, donors and donation: deceased, donors and donation: donor evaluation, donors and donation: donor-derived infections, ethics and public policy, infection and infectious agents -viral, infectious disease, liver transplantation/hepatology, organ procurement and allocation history to determine the timeline of past symptoms of COVID-19; mild COVID-19 as detection of SARS-CoV-2 in a respiratory sample in subjects with symptoms consistent with COVID-19 infection who did not require oxygen supplementation or inpatient hospitalization for COVID-19; severe COVID-19 as detection of SARS-CoV-2 in a respiratory sample in subjects with symptoms consistent with COVID-19 infection who required oxygen supplementation or inpatient hospitalization for COVID-19.

The donors underwent detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs (NPS) or bronchoalveolar lavage (BAL) and detection of IgG anti SARS-CoV-2 at recovery. According to clinical history, they underwent SARS-CoV-2 RNA evaluation before recovery, as reported in Table 1 .

SARS-CoV-2 nucleic acid was tested on liver biopsy collected at back-table, before graft reperfusion.

All recipients were tested at LT for SARS-CoV-2 nucleic acid in NPS and/or in BAL and for IgG anti-SARS-CoV-2. For the first month after LT, they underwent weekly evaluation of SARS-CoV-2 RNA in NPS and SARS CoV-2 IgG (Table 1 and Supportive Table S1 ).

In Turin LT Center, starting from November 20, 2020, all recipients were also tested for SARS-CoV-2 IgG at registration on the LT waiting list.

IgG antibodies against SARS-CoV-2 have been tested with Liaison ® SARS-CoV-2 anti-S1/S2 IgG test (DiaSorin, Saluggia Italy), cut-off value for positivity of 15 AU/ml. Sensitivity and specificity of the test is 75.6% and 100%, respectively 18 ; the positive and negative agreement with Plaque Reduction Neutralization Test is 94.4% and 97.8%, respectively, according to the manufacturer; or ARCHITECT ® SARS-CoV-2 IgG immunoassay (Abbott, Milan, Italy) with a cut-off value for positivity of 1.4 AU/ml. Sensitivity and specificity of the test is 70% and 100% respectively. 19 Neutralizing antibody (NT-Abs) against SARS-CoV2 test was performed in BSL-3 suite adapting an in-house previously reported neutralization assay. 20 Vero E6 cells were seeded at 2 × 10 4 cells/well concentration in a 96-well microtitre plate, 24 hours before the assay.

Briefly, 50 µl of plasma samples from each patient were serially diluted (from 1:10 to 1:5120) in sextuplicate and mixed with 100 median tissue culture infectious doses (TCID50) of SARS-CoV-2 virus (human strain VR PV10734, gently provided by INMI L. Spallanzani). After 1 hour incubation at 37°C, plasma and virus were transferred to Vero E6 microplates. Cells were incubated at 37°C in 5% CO 2 , for 5 days prior to microscopic evaluation of the cytopathic effect (CPE). Neutralization titer was determined by the highest plasma dilution showing a 50% reduction of CPE and evaluated according to the Reed-Muench formula. 21 Positive and negative controls were included in all test runs. 

During organ procurements and LT, the liver teams used protective equipment such as filtering face masks (NK-92, N95, FFP2, and FFP3), eye goggles and standard gloves and gowns. The organ procurements were performed using standard technique, and the livers were preserved in cold storage with Celsior solution.

Immunosuppression regimen was detailed for each patient.

By Italian law, Regional Transplantation Centers are the custodians of donor/recipient biomedical data also for research purposes. 

During the study period we enrolled 10 brain-dead donors (Table 1) with a median age of 61 years (range 14-82), median body mass (Table 1 ).

The (Table 1) . 28. All the others tested SARS-CoV-2 RNA negative on weekly NPS during the first month after LT (Supportive Table S1 ). None of the LT recipients developed COVID-19 symptoms. Table S1 ).

None of the enrolled subjects received anti-SARS-CoV-2 vaccination during the study period.

Immunosuppression was based on basiliximab induction and tacrolimus for two patients (1 and 7) , steroids, mycophenolate mofetil and tacrolimus for seven patients and tacrolimus plus everolimus in the remaining one (9).

The median post-LT hospital length of stay was 16 days (range 7-140).

After a median follow-up of 221 days (range 75-239), patient 9 died on POD75 due to sepsis caused by multidrug-resistant Acinetobacter baumannii; alpha-fetoprotein serum levels of patient 3 were found to be elevated at 3-month follow-up and chest/abdomen CT scan showed lung nodular areas which are currently treated with everolimus and sorafenib. The liver function of the nine surviving patients is satisfactory.

The COVID-19 pandemic dramatically impacted the landscape of organ donation and transplantation globally. 23, 24 This new epidemic has overwhelmed healthcare resources in some regions and forced rationing of care, including Intensive Care Unit (ICU) beds and ventilatory supports. As a consequence, organ donation and transplantation have been reduced in many countries. Overall, the progression of disease has varied but appears to be more rapid in immunocompromised hosts with greater rates of ICU admission and death. [25] [26] [27] [28] All transplantation societies strongly recommend universal screening (nucleic acid testing [NAT]) of potential deceased organ donors before procurement. 29 Donors with positive SARS-CoV-2 testing or donors with exposure risk criteria regardless of laboratory finding are generally excluded by most transplant organizations.

Transmission from infected donors to immunosuppressed recipients has been recently described with lung transplantation. 7, 14, 15, 30 In both cases, the donor tested negative for SARS-CoV-2 with upper respiratory tract sampling for nucleic acid testing, however, fore the use of these organs for vaccinated recipients is something that needs to be explored. In addition, the growing number of variants which may evade the individual natural or vaccine induced immunity is one of the major challenges we have to face in the near future. Finally, our results and the current limited published evidence suggest that organs from donors with active COVD-19 could also be used for nonimmune recipients, in particular for recipients at high risk for mortality on the waitlist. However larger studies are needed to confirm these results before recommending this possibility.

We thank the Italian Transplant Network and the organ donors and their families for their generosity.

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs

Organ procurement and transplantation during the COVID-19 pandemic

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Liver injury in COVID-19: management and challenges

Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD Expert Panel Consensus Statement

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

Use of SARS-CoV-2-infected deceased organ donors: should we always «just say no?»

Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2-positive donors

A case of coronavirus disease 2019-infected liver transplant donor

COVID-19 transmission and blood transfusion: a case report

Allogeneic haematopoietic stem cell transplantation from SARS-CoV-2 positive donors

Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: a report of 10 cases

A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors

Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing

Ten years of donor-derived disease: a report of the disease transmission advisory committee

Italian Board of Experts in Liver Transplantation (I-BELT) Study Group. Preliminary analysis of the impact of the coronavirus disease 2019 outbreak on Italian liver transplant programs

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays

Performance evaluation of Abott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test

West Nile or Usutu Virus? A Three-Year Follow-Up of Humoral and Cellular Response in a Group of Asymptomatic Blood Donors

Determination of 50% endpoint titer using a simple formula

Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor

Organ donation and transplantation during the COVID-19 pandemic: a summary of the Spanish experience

Dealing with uncertainty after transplantation in times of COVID-19

The immunocompromised transplant recipient and SARS-CoV-2 infection

UW COVID-19 SOT Study Team. COVID-19 in solid organ transplant: a multi-center cohort study

Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: a nationwide population-based study

Outcomes of COVID-19 in solid organ transplant recipients: a matched cohort study

The Canadian Donation and Transplantation Research Program. COVID-19 international recommendations for ODT

Successful double-lung transplantation from a donor previously infected with SARS-CoV-2

Interpreting diagnostic tests for SARS-CoV-2

SIREN Study Group. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Antibodies to SARS-CoV-2 are associated with protection against reinfection

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?

The data that support the findings of this study are available on request from the Corresponding author. The data are not publicly available due to privacy or ethical restrictions.